Related Articles

  • Highly purified human menotropin (HP-HMG) is associated with a low incidence of ovarian hyperstimulation syndrome (OHSS) in patients undergoing in vitro fertilization: menopur in gnrh antagonist single embryo transfer - high responder (MEGASET-HR) trial outcomes
    Fertility and SterilityVol. 109Issue 3
    • In Brief
      Agonist trigger and a freeze-only approach nearly eliminates the incidence of severe OHSS and allows physicians to safely target higher oocyte yields. However, this paradigm results in an undesirable increase in time to pregnancy, treatment cost, and patient discomfort. Moreover, whether patients benefit from cycles resulting in high numbers of retrieved oocytes (>15) remains a topic of debate.1 The infertile patient population is heterogeneous. Intuitively, individualization of treatment offers key advantages, which requires consideration of safety, efficacy, and patient-experience rather than any single parameter.
    • Full-Text
    • PDF
  • Highly purified human menotropin (HP-HMG) versus recombinant follicle stimulating hormone (RFSH) in high responders undergoing in vitro fertilization (IVF): MEGASET-HR trial outcomes
    Fertility and SterilityVol. 108Issue 3
    • In Brief
      To compare the safety/efficacy of HP-hMG (Menopur®) vs rFSH (Gonal-F®) in high responders undergoing IVF.
    • Full-Text
    • PDF
  • Mono-HP-hMG in ovarian stimulation for ART is associated with a significantly lower incidence of premature progesterone rise compared to mixed FSH-HP-hMG: is HCG-derived LH activity protective?
    Fertility and SterilityVol. 106Issue 3
    • In Brief
      The role of elevated progesterone (P4) levels on implantation success is controversial. Some studies have suggested that premature progesterone rise (PPR) (defined as peak P4 levels >1.5 ng/ml) has a detrimental effect on IVF success, while others have been unable to demonstrate a negative effect. Recent data demonstrated that using ovarian stimulation with an LH/FSH ratio in the range of 0.3-0.6 yielded the lowest chance of PPR (20%) compared with ratios < 0.3 or > 0.6 (Warner 2014), however using mono-HP-hMG (i.e a ratio of 1.0) has not been previously evaluated.
    • Full-Text
    • PDF
  • Fertility outcomes in women with hypopituitarism (HP) who undergo art treatment
    Fertility and SterilityVol. 106Issue 3
    • In Brief
      Patients with HP face many reproductive challenges. A number of studies evaluating these patients reported sub-optimal outcomes both in terms of PRs and pregnancy outcome. While new-age fertility advancements have been thought to improve treatment outcome for these patients, present data remains limited. This study shares its experience treating HP patients over the course of 13 years.
    • Full-Text
    • PDF
  • HP-HMG IN MONOTHERAPY IMPROVES CLINICAL OUTCOMES IN YOUNG WOMEN
    Fertility and SterilityVol. 114Issue 3
    • In Brief
      To evaluate the efficacy of HP-hMG ovarian stimulation in young women to tailor ART protocols to meet patient needs and improve the likelihood of a positive outcome in real world setting.
    • Full-Text
    • PDF
  • A comparison of the efficacy and safety of combined highly purified human menopausal gonadotropin (HP-hMG) and highly purified urinary follicle stimulating hormone (HP-uFSH) versus HP-hMG alone for ovarian stimulation
    Fertility and SterilityVol. 104Issue 3
    • In Brief
      To compare the efficacy and safety of a single injection of HP-hMG (Menopur®) + HP-uFSH (Bravelle®) versus HP-hMG alone for ovarian stimulation.
    • Full-Text
    • PDF
  • A prospective randomized trial to compare recombinant follicle stimulating hormone (rFSH) versus highly purified human menotropin (HP-hMG) for controlled ovarian stimulation on blastocyst aneuploidy rates
    Fertility and SterilityVol. 110Issue 4
    • In Brief
      There is some evidence that controlled ovarian stimulation (COS) protocols may affect embryo ploidy. The objective of this trial was to compare the rate of blastocyst euploidy from rFSH versus HP-hMG standardized COS protocols.
    • Full-Text
    • PDF
  • Is OHSS risk assessment by clinician accurate: incidence in young women stimulated by HP-HMG, data from a cohort study
    Fertility and SterilityVol. 104Issue 3
    • In Brief
      To describe the incidence of moderate/severe OHSS in a cohort of young women stimulated by HP-hMG for an IVF and the OHSS risk assessment by clinicians in France.
    • Full-Text
    • PDF
  • Is there any differences in serum and follicular fluid endocrine profile as well as apoptosis rate between a long-acting gonadrotopin and HP-hMG?
    Fertility and SterilityVol. 104Issue 3
    • In Brief
      To determine the endocrine profile in follicular fluid and the effectiveness in terms of metaphase II oocytes of a long-term gonadotropin versus a conventional dose daily in women participating in an oocyte donation program.
    • Full-Text
    • PDF
  • Elevated progesterone level on the day of HCG administration does not impact live birth rates following stimulation with HP-hMG and HP-FSH at a 0.5 LH/FSH ratio
    Fertility and SterilityVol. 104Issue 3
    • In Brief
      The role of elevated progesterone (P4) levels on implantation success is controversial. Some studies have suggested that premature progesterone rise (PPR) (defined as peak P4 levels >1.5 ng/ml) has a detrimental effect on IVF success, while others have been unable to demonstrate a negative effect. Recent data demonstrated that using ovarian stimulation with an LH/FSH ratio in the range of 0.3-0.6 yielded the lowest chance of PPR compared with ratios > 0.6 (Warner et al).
    • Full-Text
    • PDF